Definium Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Definium Therapeutics, Inc. (DFTX) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$158.99 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-06
- Definium Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$158.99M.
- Definium Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$77.10M.
- Definium Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$50.44M.
- Definium Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$67.27M.
- Definium Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$183.79M.
- Definium Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$108.68M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$158.99M 10-Q · filed 2026-08-06 | -$236.08M 10-Q · filed 2026-08-06 | -$286.52M derived: sum of 3 quarters · filed 2026-08-06 | -$353.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$77.10M 10-Q · filed 2026-05-07 | -$127.53M derived: sum of 2 quarters · filed 2026-05-07 | -$194.80M derived: sum of 3 quarters · filed 2026-05-07 | -$237.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$50.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$117.70M derived: sum of 2 quarters · filed 2026-02-26 | -$160.44M derived: sum of 3 quarters · filed 2026-08-06 | -$183.79M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$67.27M 10-Q · filed 2025-11-06 | -$110.01M derived: sum of 2 quarters · filed 2026-08-06 | -$133.36M 10-Q · filed 2025-11-06 | -$175.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$42.74M 10-Q · filed 2026-08-06 | -$70.86M 10-Q · filed 2026-08-06 | -$107.83M derived: sum of 3 quarters · filed 2026-08-06 | -$129.88M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$30.35M 10-Q · filed 2026-05-07 | -$65.09M derived: sum of 2 quarters · filed 2026-05-07 | -$87.13M derived: sum of 3 quarters · filed 2026-05-07 | -$106.43M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$34.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$56.78M derived: sum of 2 quarters · filed 2026-02-26 | -$76.08M derived: sum of 3 quarters · filed 2026-02-26 | -$108.68M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$22.04M 10-Q · filed 2025-11-06 | -$41.34M derived: sum of 2 quarters · filed 2025-11-06 | -$73.94M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$19.30M 10-Q · filed 2025-07-31 | -$60.25M 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | -$54.40M 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.223B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B |